Company intelligence / Profile preview

Sophiris Bio Inc.

San Diego, California, United Statesannualreports.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Sophiris Bio completed a Phase 3 "PLUS-1" study for PRX302 (topsalysin) for BPH treatment, which met its primary endpoint with a statistically significant improvement in International Prostate Symptom Score (IPSS) total score from baseline over 12 months compared to the control group (7.60 vs. 6.58 point improvement; p = 0.043). The company also completed Phase 2 clinical trials for the focal treatment of localized prostate cancer. However, the company announced a shutdown of operations in May 2020 after being delisted from Nasdaq in March 2020.

Therapeutic areas: Men's HealthOncology
Modalities: Protein-based therapeutics
Industry: Biotech

Drug pipeline

2 assets

topsalysin

1 more asset in the full pipeline.

Request access →

Partnerships

Kissei Pharmaceutical Co., Ltd.

Beyond the preview

Go deeper on Sophiris Bio Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sophiris Bio Inc..

Explore the full profile